Uveitis - Epidemiology Forecast - 2032

DelveInsight's'Uveitis - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the Uveitis, historical and forecasted epidemiology, and the Uveitis trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Uveitis Understanding

Uveitis is a serious intraocular inflammatory disorder of the uveal tract, often associated with visual impairment, blindness, and decreased quality of life. It often affects patients in their most active and economically productive years. It is the leading cause of preventable blindness worldwide and is a critically underserved disease in terms of treatment.

It encompasses a diverse group of inflammatory ocular diseases and may also affect the lens, retina, optic nerve, and vitreous humor (the gel-like fluid inside the eye). An injury, infection, a tumor in the eye, or an autoimmune or inflammatory condition may cause it. One or both eyes may be affected. The signs and symptoms include redness and pain in the eye, sensitivity to light, blurred vision, dark floating spots in the vision, and vision loss. If not treated, uveitis can lead to tissue scarring and blindness.

It is broadly classified as infectious and noninfectious. Infectious uveitis can result from bacteria or viruses in the eye, while noninfectious uveitis (NIU) can occur with systemic autoimmune disease and autoimmune diseases localized to the eye. Diseases like juvenile idiopathic arthritis (JIA), Behcet's disease, Vogt-Koyanagi-Harada syndrome, and sarcoidosis are associated with uveitis. While macular edema (ME), cataracts, and glaucoma are the common complications of uveitis.

Uveitis Diagnosis

A thorough eye exam is needed to diagnose uveitis. Diagnosis begins with a comprehensive symptom review and a thorough exam of both the anterior and posterior segments. The clinical diagnosis is often based on spillover inflammation (i.e., cells and protein flare) observed with a slit lamp in the aqueous or vitreous humor. Further, blood tests and x-rays may be used to determine whether another underlying systemic disorder is causing the condition. Ophthalmoscopy, also known as funduscopy, involves dilating the pupil with eye drops and shining a bright light into the eye to examine the back of the eye is also a widely used technique. Other techniques for diagnosis include fluorescein angiography or indocyanine green angiography and optical coherence tomography (OCT) imaging to map the swelling of the retina and choroid besides radiography, CT, or MRI scans.

Continued in the report…..

Uveitis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total diagnosed prevalence of uveitis, total diagnosed prevalence of ME associated with uveitis, type-specific diagnosed prevalence of uveitis, diagnosed prevalence of uveitis by anatomical location, and etiology-specific diagnosed prevalence of uveitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Uveitis Detailed Epidemiology Segmentation

• In 2022, the total diagnosed prevalence of uveitis in the 7MM were estimated to be approximately 1,013,902 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.2% during the study period (2019-2032).
• As per the estimates by DelveInsight, the total diagnosed prevalent cases of ME associated with uveitis in the 7MM were estimated to be approximately 257,762 cases in the 7MM. These cases are expected to increase by 2032.
• Among the 7MM, the United States accounted for approximately 38% of the total diagnosed prevalent cases of uveitis in the year 2022, which is expected to increase further during the study period (2019-2032).
• Among the 7MM, Japan accounted for the second-highest total diagnosed prevalent cases of uveitis in 2022, with approximately 214,892 cases. However, these cases are anticipated to decrease by 2032.
• In 2022, the type-specific cases of uveitis included infectious uveitis and NIU, which were approximately 34,105 and 348,778 cases, respectively, in the US. These numbers are expected to rise during the study period (2019-2032).
• In 2022, there were approximately 203,551 cases of anterior uveitis, followed by approximately 84,206 cases of posterior, 81,861 cases of the pan, and 46,510 cases of intermediate uveitis, respectively, in EU4 and the UK. According to DelveInsight'sestimates, these are expected to increase during the study period (2019-2032).
• The etiology-specific diagnosed prevalent cases of uveitis were grouped into HLA-B27-associated uveitis, sarcoidosis, Behcet's disease, Vogt-Koyanagi-Harada disease, ankylosing spondylitis, JIA, herpes, tuberculosis, idiopathic and others. In the 7MM, among the different etiologies, idiopathic etiology accounted for the highest cases of uveitis, with approximately 430,676 cases, while JIA accounted for the least, with approximately 17,641 cases in 2022. The cases are expected to increase by 2032.

Scope of the Report:

• The report covers a descriptive overview of uveitis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of uveitis.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, total diagnosed prevalence of uveitis, total diagnosed prevalence of ME associated with uveitis, type-specific diagnosed prevalence of uveitis, the diagnosed prevalence of uveitis by anatomical location, and etiology-specific diagnosed prevalence of uveitis.

Report Highlights:

• Ten years forecast of uveitis
• The 7MM coverage
• Total diagnosed prevalence of uveitis
• Total diagnosed prevalence of ME associated with uveitis
• Type-specific diagnosed prevalence of uveitis
• Diagnosed prevalence of uveitis by anatomical location
• Etiology-specific diagnosed prevalence of uveitis

Key Questions Answered

• What are the disease risk and burdens of uveitis?
• What is the historical Uveitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of uveitis at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with uveitis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of uveitis during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy:

The Uveitis report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM Uveitis epidemiology forecast.
• The Uveitis epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Uveitis epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032